Amphastar Receives FDA Approval for Generic Ipratropium Bromide HFA Inhalation Aerosol
Published: 17 Mar 2026
Author: Precedence Research
Amphastar Secures FDA Approval for Ipratropium Bromide HFA
In February 2026, Amphastar Pharmaceuticals (NASDAQ: AMPH) received FDA approval for its generic Ipratropium Bromide HFA Inhalation Aerosol. This bioequivalent, 180-day exclusive, generic version of Atrovent® HFA is scheduled for launch in early Q2 2026.
FDA approval for Ipratropium Bromide HFA
Ipratropium is an anticholinergic medication used for the long-term management of COPD-related bronchospasm, including emphysema and chronic bronchitis. IQVIA data shows that Atrovent® HFA generated roughly $112 million in U.S. sales during the 2025 calendar year. This approval boosts Amphastar’s portfolio of high-value and complex inhalation products. Amphastar is set to release its Ipratropium Bromide HFA Inhalation Aerosol (formerly AMP-007) in early Q2 2026.
According to Towards Chem&Materials, the bromine market size accounted for USD 3.11 billion in 2025 and is predicted to increase from USD 3.29 billion in 2026 to approximately USD XX billion by 2035, expanding at a CAGR of 5.65% from 2026 to 2035 as adoption of bromine in high-growth areas is increasing globally.
Pipeline Information
The company’s current pipeline targets market opportunities totaling over $6.4 billion. This includes a filed ANDA and a biosimilar insulin (targeting $1.7 billion), two biosimilars in development (targeting $3.7 billion), and two generics in development (targeting $1 billion).
Industry Shift to Sustainability Accelerates the Bromine Market
- Market players are transitioning towards sustainable and polymeric flame retardants to fulfil strict environmental regulations and prevent toxicity issues related to conventional additives.
- Surge in R&D in hydrogen bromine and zinc-bromine flow batteries for renewable energy storage is fuelling product demand.
Major players such as Lanxess AG, Albemarle Corporation, and ICL Group are growing their manufacturing capabilities, especially in the Middle East, simultaneously investing in high-performance and sustainable solutions. - High-purity hydrogen bromide (HBr) is increasingly becoming indispensable for cutting-edge plasma etching in chip production, enabling market players to command premium pricing.
- High-density clear brine fluids (calcium and zinc bromide) are critical for deepwater and high-pressure drilling, contributing roughly 25%–30% of total market revenue.